Engineering Hepatocyte-Targeted LNPs For RNA And DNA Delivery To Primary Human T Cells

Electroporation struggles with large-insertion DNA payloads in primary human T cells, often achieving less than 20% insertion efficiency. Proprietary lipid nanoparticle formulations developed by ElevateBio researchers were engineered with ionizable lipids and hydrolysable PEG-lipids to address this gap across both RNA and DNA delivery modalities.

The data presented here show that these LNPs outperformed a commercial benchmark in eGFP mRNA delivery, achieving greater than 90% eGFP-positive T cells with viability comparable to untreated controls. For CAR T cell engineering, LNPs surpassed electroporation in CAR mRNA delivery and reached up to 88% CD19-CAR insertion efficiency using a novel recombinase system. Greater than 85% TRAC knockout was also achieved via RNA-LNP delivery of proprietary nuclease constructs.

Download the full poster to examine the formulation approach and performance data across payload types.